Casdin Capital’s CytomX Therapeutics CTMX Stock Holding History

Casdin Capital’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-207,500	Closed	-$3.84M	–	33
2018 Q3	$3.84M	Hold	207,500	–	–	0.47%	34
2018 Q2	$4.74M	Hold	207,500	–	–	0.66%	27
2018 Q1	$5.9M	Buy	207,500 +30,000	+17%	+$856K	1.04%	24
2017 Q4	$3.75M	Hold	177,500	–	–	0.91%	22
2017 Q3	$3.23M	Hold	177,500	–	–	0.91%	23
2017 Q2	$2.75M	Hold	177,500	–	–	1.02%	26
2017 Q1	$3.06M	Buy	177,500 +50,000	+39%	+$658K	1.81%	20
2016 Q4	$1.4M	Hold	127,500	–	–	1.16%	22
2016 Q3	$2M	Sell	127,500 -106,679	-46%	-$1.29M	1.62%	21
2016 Q2	$2.39M	Sell	234,179 -86,844	-27%	-$990K	2.38%	15
2016 Q1	$4.14M	Hold	321,023	–	–	4.75%	11
2015 Q4	$6.7M	Buy	+321,023	New	+$5.08M	5.92%	4

Other funds holding CTMX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Casdin Capital's CTMX Position: Q4 2018 in Review

Casdin Capital sold out of CytomX Therapeutics (CTMX) in Q4 2018, closing a stake of 207,500 shares — an estimated $3.84M sold.

Casdin Capital first reported a position in CTMX in Q4 2015 and held it in 12 quarters. The position peaked at $6.7M in Q4 2015. 111 funds tracked by Wall St. Rank hold CTMX as of Q4 2018.

Casdin Capital reported no remaining CytomX Therapeutics position as of Q4 2018 after selling out during the quarter.
Casdin Capital sold 207,500 CytomX Therapeutics shares in Q4 2018, an estimated $3.84M.
Casdin Capital first reported a position in CytomX Therapeutics in Q4 2015 and held it in 12 quarters.
Casdin Capital's CytomX Therapeutics position peaked at $6.7M in Q4 2015.
111 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q4 2018.

Based on Casdin Capital's 13F filing for Q4 2018, filed 13 Feb 2019.